Document is current
Any future updates will be listed below
-
Authors
Peck, Stephanie Knatz https://orcid.org/0000-0001-9421-9158
Shao, Samantha
Gruen, Tessa
Yang, Kevin https://orcid.org/0000-0002-1451-258X
Babakanian, Alexandra
Trim, Julie
Finn, Daphna M. https://orcid.org/0000-0003-2572-7778
Kaye, Walter H. https://orcid.org/0000-0002-4478-4906
-
Funding
Funding for this research was provided by:
Compass Pathways
- License Information
-
More Information
Article History
Received: 27 October 2022
Accepted: 9 June 2023
First Online: 24 July 2023
Change Date: 27 July 2023
Change Type: Update
Change Details: In the version of this article initially published, the ClinicalTrials.gov ID was not included in the Abstract and is now amended in the HTML and PDF versions of the article.
Competing interests
: S.K.P. is a senior clinical consultant for Compass Pathways, the funder of the study, and receives compensation for this role. Additionally, she is a sub-investigator for an upcoming Compass-sponsored randomized trial evaluating psilocybin for anorexia nervosa and is a lead therapist for this trial and other Compass-sponsored trials. W.H.K. has served as a consultant and advisor for Compass Pathways, the funder of this study, and has received compensation for these roles. W.H.K. has also received financial support for this study and for an upcoming randomized controlled trial evaluating psilocybin for anorexia nervosa, which is sponsored by Compass Pathways. Additionally, he serves as site principal investigator for the upcoming referenced trial. S.S., T.G., K.Y., A.B., J.T. and D.F.M. report no competing interests.
